Glenmark Pharmaceuticals Receives ANDA Approval for Chlorzoxazone Tablets USP, 375 mg and 750 mg; Glenmark's First ANDA Approval out of Their New U.S. Facility
MUMBAI, May 27, 2020 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Chlorzoxazone Tablets USP, 375 mg and 750 mg. This marks Glenmark's first ANDA approval out of their new North American manufacturing facility based in Monroe, North Carolina.
According to IQVIA™,1 sales data for the 12 month period ending March 2020, the Chlorzoxazone Tablets, 375 mg and 750 mg market2 achieved annual sales of approximately $20.9 million*.
Glenmark's current portfolio consists of 163 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
1 All brand names and trademarks are the property of their respective owners.
2 Market includes brand and all available therapeutic equivalents
* IQVIA™ National Sales Perspectives: Retail & Non-Retail, March 2020
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For more information, visit www.glenmarkpharma.com
Logo: https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg
Share this article